Company news
Fulcrum Therapeutics, Inc. news in 2022
Fulcrum Therapeutics, Inc.'s news releases, calls and decks from 2022, newest first.
Fulcrum Therapeutics to Participate at Upcoming 2022 BofA Securities Biotech SMID Cap Conference
November 30, 2022
Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 10, 2022
Fulcrum Therapeutics Announces Recent Business Highlights and Third Quarter 2022 Financial Results
November 7, 2022
Fulcrum Therapeutics Appoints Chief Medical Officer and Chief Scientific Officer
November 6, 2022
Fulcrum Therapeutics® to Host Third Quarter 2022 Financial Results Conference Call and Webcast on Tuesday, November 8, 2022 at 8: 00 a.m. ET
November 1, 2022
Fulcrum Therapeutics® to Participate at Upcoming November Investor Conferences
October 31, 2022
Fulcrum Therapeutics to Present New Data from the Open Label Extension of Phase 2 ReDUX4 Study at the World Muscle Society (WMS) Congress in Halifax, Canada
October 11, 2022
Fulcrum Therapeutics to Participate at Upcoming September Investor Conferences
September 5, 2022
Fulcrum Therapeutics® to Participate at the Upcoming Stifel 2022 Biotech Summer Summit
August 15, 2022
Fulcrum Therapeutics Announces Pricing of Public Offering of Common Stock
August 14, 2022
Fulcrum Therapeutics Announces Second Quarter 2022 Financial Results and Business Update
August 10, 2022
Fulcrum Therapeutics® to Host Second Quarter 2022 Financial Results Conference Call and Webcast on Thursday, August 11, 2022 at 8: 00 a.m. ET
August 3, 2022
Fulcrum Therapeutics Announces Departure of Chief Medical Officer
July 10, 2022
Fulcrum Therapeutics Enrolls First Patient in Pivotal Global Phase 3 Clinical Trial of Losmapimod for Facioscapulohumeral Muscular Dystrophy (FSHD)
July 4, 2022
Fulcrum Therapeutics Announces Proof-of-Concept for FTX-6058 in Sickle Cell Disease Based on Initial Data from the Ongoing Phase 1b Trial
June 9, 2022
Fulcrum Therapeutics to Present Initial Data from Phase 1b Trial of FTX-6058 in Adults Living with Sickle Cell Disease at the European Hematology Association (EHA) Hybrid Congress in Vienna, Austria
May 11, 2022
Fulcrum Therapeutics Reports Recent Business Highlights and First Quarter 2022 Financial Results
May 8, 2022
Fulcrum Therapeutics to Participate at the Upcoming BofA Securities 2022 Healthcare Conference
May 4, 2022
Fulcrum Therapeutics to Host First Quarter 2022 Financial Results Conference Call and Webcast on Monday, May 9, 2022 at 8: 00 a.m. ET
May 1, 2022
Fulcrum Therapeutics® Announces Multiple Presentations on FSHD at the American Academy of Neurology’s Annual Meeting
March 31, 2022
Fulcrum Therapeutics® to Host Virtual Key Opinion Leader Webcast Featuring Losmapimod for Facioscapulohumeral Muscular Dystrophy (FSHD)
March 16, 2022
Fulcrum Therapeutics® Presents Data Highlighting Reachable Workspace (RWS) as Relevant Functional Endpoint in Facioscapulohumeral Muscular Dystrophy (FSHD) at MDA Clinical and Scientific Conference
March 13, 2022
Fulcrum Therapeutics® Reports Recent Business Highlights and Fourth Quarter and Full Year 2021 Financial Results
March 2, 2022
Fulcrum Therapeutics® Announces REACH, a Phase 3 Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)
March 2, 2022
Fulcrum Therapeutics® to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call and Webcast on Thursday, March 3, 2022 at 8: 00 a.m. ET
February 23, 2022
Fulcrum Therapeutics® to Participate in 11th Annual SVB Leerink Global Healthcare Conference
February 9, 2022
Fulcrum Therapeutics® Announces Upcoming Milestones to Support Its Mission of Treating the Root Cause of Rare Genetic Diseases
January 9, 2022
Fulcrum Therapeutics® to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 5, 2022
Fulcrum Therapeutics® Appoints Esther Rajavelu as Chief Financial Officer
January 3, 2022
Calls in 2022
- Fulcrum Therapeutics (NASDAQ:FULC) Q3 2022 Earnings Call
Nov 8, 2022
Transcript - Fulcrum Therapeutics (NASDAQ:FULC) Q2 2022 Earnings Call
Aug 11, 2022
Transcript - Fulcrum Therapeutics (NASDAQ:FULC) Q1 2022 Earnings Call
May 9, 2022
Transcript - Fulcrum Therapeutics (NASDAQ:FULC) Q4 2021 Earnings Call
Mar 3, 2022
Transcript